WuXi STA bringing about 500 jobs to Middletown
WILMINGTON, Del. (June 28, 2021) — WuXi STA and Delaware Prosperity Partnership today announced that WuXi STA, a leading Contract Development and Manufacturing Organization (CDMO), will build a new pharmaceutical manufacturing campus in Middletown, Delaware. The state-of-the-art WuXi STA Middletown Site, which is expected to open in 2024 and be its first on the East Coast, will be located at 1091 Industrial Drive in Middletown Business Center and aims to bring about 500 new full-time jobs to Delaware by 2026.
“This is an investment in good jobs that will drive economic growth in southern New Castle County and across Delaware,” said Governor John Carney. “I want to be the first to welcome WuXi STA to our great state. Over the next five years, WuXi STA plans to build a state-of-the-art pharmaceutical manufacturing campus in one of Delaware’s fastest-growing communities. This campus will build on our strength in biopharmaceuticals – and it’s only possible because of Delaware’s world-class, innovative workforce. Thank you to WuXi STA, Middletown Mayor Kenny Branner and everyone who made this project possible.”
“WuXi STA is excited to join Delaware’s growing healthcare community and establish Middletown as the home of our new state-of-the-art pharmaceutical clinical and commercial manufacturing complex,” said Minzhang Chen, CEO of WuXi STA. “Delaware’s highly trained pharmaceutical manufacturing workforce and proximity to many of our customers provide tremendous opportunities to support the region’s economic growth and efforts to advance pharmaceutical development and manufacturing. We are grateful to Delaware and Middletown for their leadership in fostering a strong entrepreneurial and innovation ecosystem, and we look forward to collaborating to deliver groundbreaking treatments for patients.”
There is growing industry and local customer demand for innovative technologies to help companies advance pharmaceutical discovery and development throughout the pre-clinical, clinical and manufacturing pipelines. As an industry-leading global CDMO, WuXi STA provides customers with one-stop manufacturing services for both drug substance and drug product, including oral and injectable dosage forms. The new facility in Middletown will feature space for testing laboratories; manufacture of active pharmaceutical ingredients (APIs); and manufacture and packaging of solid dosage pharmaceutical products and sterile products. Jobs at the site will include manufacturing operators, lab technicians, quality assurance and quality control staff, scientists and management, administrative and warehouse support staff. Supporting WuXi STA’s plans are grants that the company was approved to receive from the Delaware Strategic Fund by the state Council on Finance Development.
“This campus on 190 acres is going to add a tremendous diversity of good jobs to Middletown, New Castle County and Delaware as a whole. WuXi STA’s selection of Middletown reinforces what we do here, adds great value to what we have been working on for many years and shows us they have confidence in us, to want to be a part of what we have built here,” said Middletown Mayor Kenny Branner, who added he would like to thank the governor and the several state departments the town has been working with, especially Delaware Prosperity Partnership (DPP) and Kurt Foreman, president & CEO of DPP.
“We win the future by attracting global leading healthcare firms like WuXi STA to New Castle County,” said New Castle County Executive Matt Meyer. “This project will bring hundreds of good-paying jobs to the area and will advance New Castle County’s goal of growing our biotech industry. We welcome WuXi STA to New Castle County and look forward to its partnerships in Middletown and all across our community as it looks to fill jobs from our local and talented workforce.”
WuXi STA joins numerous other in companies choosing Middletown for growth in large-scale sites. The new facility will be near Middletown’s one million square-foot Amazon fulfillment center, as well as Datwyler Sealing Solutions’ 200,000 square-foot Middletown manufacturing plant and Breakthru Beverage’s new 285,000 square-foot headquarters.
WuXi STA currently provides pharmaceutical development and manufacturing solutions for over 470 partners worldwide, covering small molecules and novel molecular modalities such as oligonucleotide, peptide and various complex conjugates. The future Middletown site will become WuXi STA’s second site in the U.S., and will contain state-of-the-art pharmaceutical clinical and commercial manufacturing capabilities. The 190-acre campus will be home to WuXi STA’s 8th global manufacturing facility.
WuXi STA’s current project plan is an initial phase for this new campus. Subsequent phases could further expand its campus in Middletown to a total workforce of more than 1,000 employees.
About Delaware Prosperity Partnership
Delaware Prosperity Partnership (choosedelaware.com) leads Delaware’s economic development efforts to attract, grow and retain businesses; to build a stronger entrepreneurial and innovation ecosystem; and to support private employers in identifying, recruiting and developing talent. The DPP team works with site selectors, executives and developers focused on where to locate or grow a business and helps with reviewing potential sites, cost-of-living analyses and funding opportunities, including available tax credits and incentives. DPP advances a culture of innovation in Delaware, working with innovators and startups to spotlight and celebrate successes and connect them with the resources they need to succeed. DPP and its partnerships throughout Delaware support and advance the missions of companies of all sizes and sectors.
About WuXi STA
WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier contract development and manufacturing organization (CDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and control (CMC) from preclinical to commercial uses.